Substitution mutational signatures in whole-genome-sequenced cancers in the UK population

Whole-genome sequencing (WGS) permits comprehensive cancer genome analyses, revealing mutational signatures, imprints of DNA damage, and repair processes that have arisen in each patient's cancer. We performed mutational signature analyses on 12,222 whole-genome-sequenced tumor-normal matched pairs from patients recruited via the UK National Health Service (NHS). We contrasted our results with two independent cancer WGS datasets-from the International Cancer Genome Consortium (ICGC) and the Hartwig Medical Foundation (HMF)-involving 18,640 whole-genome-sequenced cancers in total. Our analyses add 40 single and 18 double substitution signatures to the current mutational signature tally. We show for each organ that cancers have a limited number of common signatures and a long tail of rare signatures, and we provide a practical solution for applying this concept of common versus rare signatures to future analyses.

Automated summary

Whole-genome sequencing allows for comprehensive analysis of cancer genomes, revealing mutational signatures and DNA repair processes. This study analyzed 12,222 tumor-normal matched samples using mutational signature analysis. The results showed that tumors in each organ have a limited number of common signatures and a long tail of rare signatures, providing a practical solution for future analyses.